Literature DB >> 1474773

Success of kidney transplantation in oxalosis is unrelated to residual hepatic enzyme activity.

A Katz1, D Freese, C J Danpure, J I Scheinman, S M Mauer.   

Abstract

We evaluated hepatic alanine glyoxylate aminotransferase (AGT) activity in percutaneous hepatic biopsy material obtained from four children with long-term renal allograft function following transplantation for primary hyperoxaluria type 1 (PH 1). The study was performed to determine whether these successes had occurred because relatively high residual levels of AGT activity had introduced a selection bias. The children ranged from seven months to eight years at transplant and are currently well 7 to 11 years later, with no oxalate deposition on repeated allograft biopsies and creatinine clearances of 80 to 128 ml/min/1.73 m2. AGT activity ranged from 0 to 13.8%, and in two of three patients with detectable levels the AGT was in mitochondria rather than peroxisomes. These results indicate that long-term renal allograft success can occur in spite of severe AGT deficiency. Thus, the therapeutic choice of kidney alone versus combined kidney-liver transplant cannot currently be made by measuring residual hepatic AGT in PH 1. Kidney transplant alone remains a reasonable initial therapeutic alternative for patients with recent onset of renal insufficiency due to PH 1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474773     DOI: 10.1038/ki.1992.434

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  2 in total

1.  Initial manifestation of primary hyperoxaluria type I in adults-- recognition, diagnosis, and management.

Authors:  J J Kuiper
Journal:  West J Med       Date:  1996-01

2.  Transplantation outcomes in patients with primary hyperoxaluria: a systematic review.

Authors:  Elisabeth L Metry; Liza M M van Dijk; Hessel Peters-Sengers; Michiel J S Oosterveld; Jaap W Groothoff; Rutger J Ploeg; Vianda S Stel; Sander F Garrelfs
Journal:  Pediatr Nephrol       Date:  2021-04-08       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.